Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2018 |
| gptkbp:ATCCode |
L04AA44
|
| gptkbp:brand |
gptkb:Ultomiris
|
| gptkbp:CASNumber |
1448221-90-9
|
| gptkbp:developedBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:halfLife |
32 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
ravulizumab
|
| gptkbp:indication |
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:atypical_hemolytic_uremic_syndrome |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:IgG2/4_kappa
|
| gptkbp:mechanismOfAction |
complement C5 inhibitor
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea diarrhea headache upper respiratory tract infection |
| gptkbp:target |
gptkb:complement_protein_C5
|
| gptkbp:UNII |
6U8K4O1Y8J
|
| gptkbp:usedFor |
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:atypical_hemolytic_uremic_syndrome |
| gptkbp:bfsParent |
gptkb:PNH
|
| gptkbp:bfsLayer |
6
|